Patents Assigned to CELL MEDICA SWITZERLAND AG
  • Nucleic acid encoding antibody to human IL-1 beta
    Patent number: 10626171
    Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: April 21, 2020
    Assignee: Cell Medica Switzerland AG
    Inventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Thorsten Alexander Schafer
  • TNF alpha antibody or fragment thereof and methods of use
    Patent number: 10233238
    Abstract: The present invention relates to anti-TNF alpha binding members and in particular to monovalent, high potency TNF alpha-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: March 19, 2019
    Assignee: Cell Medica Switzerland AG
    Inventors: Abdijapar Shamshiev, Titus Kretzschmar
  • BINDING MEMBERS TO PD-L1
    Publication number: 20190055312
    Abstract: The present invention relates to anti-PD-L1 binding members and in particular to monovalent, high potency PD-L1-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of cancer and inflammatory diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Application
    Filed: February 24, 2017
    Publication date: February 21, 2019
    Applicant: Cell Medica Switzerland AG
    Inventors: Abdijapar Shamshiev, Titus Kretzschmar, Miriam Droste, Douglas Phillips
  • Method of inhibiting human IL-1 beta by administering an antibody to human IL-1 beta
    Patent number: 10077302
    Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: September 18, 2018
    Assignee: Cell Medica Switzerland AG
    Inventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Thorsten Alexander Schafer
  • Antibodies against IL-1 beta
    Patent number: 9914772
    Abstract: The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: March 13, 2018
    Assignee: Cell Medica Switzerland AG
    Inventors: Annemarie Honegger, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Stefanie Grabulovski
  • Nucleic acid encoding antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
    Patent number: 9512411
    Abstract: The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: December 6, 2016
    Assignee: CELL MEDICA SWITZERLAND AG
    Inventors: Adrian Auf Der Maur, Alcide Barberis, Peter Lichtlen